Medac Pharma announced the launch of Rasuvo (methotrexate) injection for patients with rheumatoid arthritis, polyarticular course juvenile idiopathic arthritis (pJIA), and psoriasis, following its approval in July 2014.

Rasuvo is a subcutaneous autoinjector that contains methotrexate, a folate analog metabolic inhibitor. It works by interfering with DNA synthesis, repair, and cellular replication.

The company has also launched CORE Connections, a program that provides information, materials, and assistance to help patients and healthcare providers use Rasuvo.

RELATED: FDA Approves Rasuvo Injection for RA, JIA, Psoriasis

Rasuvo autoinjector is available in the following dosage strengths: 7.5mg/0.15mL, 10mg/0.20mL, 12.5mg/0.25mL, 15mg/0.30mL, 17.5mg/0.35mL, 20mg/0.40mL, 22.5mg/0.45mL, 25mg/0.50mL, 27.5mg/0.55mL, and 30mg/0.60mL in 1- and 4-count packs.

For more information call (855) 336-3322 or visit